ERBB2 and neoplasm: The group of Okazaki et al. (2018) have reported in only 18 ER-positive, HER2-negative MBC patients on EVE/EXE, that PFS was not significantly different between patients with high or low p-S6RP(Ser235/236) in primary tumour tissue.